focus is on the practices that U.S. regulatory agencies use for assessing cancer risk, although we also provide a brief … emphasis on ex ante measurements of individuals' willingness to pay for risk reductions. We present the underlying theory, the … also provides an overview of the current methodology for valuing risks of both mortality and morbidity, placing particular …

contingent valuation surveys that elicit the willingness to pay (WTP) for mortality risk reductions. We examine the importance of …

in levels of fatal risk. The paper contrasts VSL estimates from conventional analysis with the bounds obtained under this … hedonic methods. Usually strong enough assumptions are made on the functional form of utility to point identify individuals … partial identification without relying on functional form restrictions for utility. Identification given general, potentially …

in levels of fatal risk. The paper contrasts VSL estimates from conventional analysis with the bounds obtained under this … hedonic methods. Usually strong enough assumptions are made on the functional form of utility to point identify individuals … partial identification without relying on functional form restrictions for utility. Identification given general, potentially …

cancer mortality risk when answering the valuation questions. We estimate the cancer VSL to be between € 1.9 and 5.7 million … in the first place). The product of these two probabilities is the unconditional cancer mortality risk. Our hypothetical …, depending on whether the (unconditional) mortality risk was reduced by lowering the chance of getting cancer, increasing the …